Clinical trial NCT05407766: Mesenchymal Stem Cells (MSCs) for Perianal Fistula
Official title: A Phase I Safety Study of Allogeneic Bone Marrow Derived MSCs for Refractory Perianal Fistulizing Crohn's Disease
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Rectal Fistula
Lead sponsor: Ossium Health, Inc.
Sponsor class: INDUSTRY
First posted: 2022-06-07
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: OSSM-001 will be evaluated in a double blind, randomized phase I safety study of a single injection of 100 and 300 million bone marrow derived MSCs in 16 patients with refractory perianal fistulas in the setting of Crohn's disease. There will be 2 cohorts (100M and 300M MSCs); 8 subjects in each cohort; 6 subjects receiving the investigational product and 2 subjects receiving placebo (normal saline) in each cohort.


Eligibility criteria: Inclusion Criteria:

* Men and Women 18-75 years of age with a diagnosis of unhealing perianal fistulas in the setting of Crohn's disease and must be on maximal standard of care therapy (e.g., antibiotics, 5-ASA, and immunomodulator, anti-TNF, anti-integrin, and anti-interleukin therapies) for at least six months duration.
* Presence of perianal fistula with maximum of two internal fistula tracts and a maximum of three external openings based on clinical assessment and MRI. Fistula must have been draining for at least 6 weeks prior to the screening visit.
* Medically refractory perianal fistulizing Crohn's disease (i.e., standard of care such as antibiotics, immunosuppressives)
* Have no contraindications to MR evaluations: e.g., pacemaker or magnetically active metal fragments, claustrophobia
* Ability to comply with protocol
* Competent and able to provide written informed consent
* Concurrent Crohn's-related therapies with stable doses corticosteroids, 5- ASA drugs, immunomodulators, anti-TNF therapy, anti-integrin and anti-interleukin therapies are permitted.
* A female participant and of childbearing potential must have a negative serum or urine pregnancy test at time of screening, and must not plan to become pregnant during the study.

Exclusion Criteria:

* Inability to give informed consent.
* Clinically significant medical conditions within the six months before administration of MSCs: e.g. myocardial infarction, active angina, congestive heart failure or other conditions that would, in the opinion of the investigators, compromise the safety of the patient.
* Specific exclusions: Hepatitis B or C, HIV, Abnormal AST or ALT at screening
* History of cancer including melanoma (with the exception of localized skin cancers) in the past five years
* Received treatment with an investigational drug or device within 60 days of randomization or have not completed 5 half-life washout (whichever is later) for drugs or biologics. If the half-life of the product is not known, then subjects cannot be randomized within 6 months of investigation drug treatment.
* Participated in a cell therapy-based trial within 6 months before randomization
* Participated in Crohn's/ulcerative colitis or any fistulizing Crohn's study within 6 months before randomization
* Pregnant or breast feeding or trying to become pregnant.
* Presence of a rectovaginal or perineal body fistula
* Change in Crohn's immunosuppressive regimen prior to enrollment. Subjects should be on stable, maximal medical therapy for 4 months prior to enrollment.
* Uncontrolled intestinal Crohn's disease which will require escalation for medical therapy or surgery within 3 months of enrollment
* Severe anal canal disease that is stenotic and requires dilation or severe proctitis making difficult to the surgery
* A female or male participant unwilling to agree to use acceptable contraception methods during participation in study. Acceptable contraception methods include: Implants, injectables, combined oral contraceptives, an intrauterine device, a bilateral tubal ligation, a vasectomy, a vasectomized partner for female participant, double-barrier methods, and physical barrier if male participant is not vasectomized
* Associated perianal abscess(es).
* Laboratory exclusions: Serum creatinine levels \>1.5 times the upper limit of normal (ULN). Total bilirubin \>1.5 × ULN. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>5.0 × ULN. Hemoglobin \<10.0 g/dL for females or \<11.0 g/dL for males. Platelets \<75.0 × 109/L.
* Any contraindications to MRI or surgical or anesthetic procedure(s)
* Any major GI surgery or major perianal local surgery within 6 months of randomization

Primary outcomes:
measure: OSSM-001 (100M dose) related adverse events as assessed by CTCAE v5.0
timeFrame: 12 weeks
measure: OSSM-001 (300M dose) related adverse events as assessed by CTCAE v5.0
timeFrame: 12 weeks
Secondary outcomes:
measure: Fistula healing assessed by radiographic (MRI) assessments for OSSM-001 (100M dose)
timeFrame: 12 weeks
measure: Fistula healing assessed by clinical assessments for OSSM-001 (100M dose)
timeFrame: 12 weeks
measure: Fistula healing assessed by radiographic (MRI) assessments for OSSM-001 (300M dose)
timeFrame: 12 weeks
measure: Fistula healing assessed by clinical assessments for OSSM-001 (300M dose)
timeFrame: 12 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Ossium Health, Inc.
name: Sagar Munjal, MD
role: STUDY_DIRECTOR
affiliation: The Cleveland Clinic
name: Amy Lightner, MD
role: PRINCIPAL_INVESTIGATOR
References: